Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond

Hossein A. Ghofrani*, Ian H. Osterloh‡ and Friedrich Grimminger*

Abstract | In less than 20 years, the first selective type 5 phosphodiesterase inhibitor, sildenafil, has evolved from a potential anti-angina drug to an on-demand oral treatment for erectile dysfunction (Viagra), and more recently to a new orally active treatment for pulmonary hypertension (Revatio). Here we describe the key milestones in the development of sildenafil for these diverse medical conditions, discuss the advances in science and clinical medicine that have accompanied this journey and consider possible future indications for this versatile drug.

However, the therapeutic potential of nitrates is limited by the rapid induction of tachyphylaxis with prolonged administration. This limitation led some scientists at Pfizer to consider alternative approaches to modulate NO signalling.

PDE5 is selected as a target

Although the precise mechanism of tolerance to nitrates is not clear, any treatment that does not directly increase NO levels might circumvent this problem. The scientific team at Pfizer therefore proposed that a downstream target in the NO/cGMP pathway could be modulated. Cyclic nucleotides (cAMP and cGMP) are degraded by a cascade of reactions that ultimately decreases intracellular levels of cAMP and cGMP. Nitrates were and still are in widespread clinical use for the treatment of cardiovascular diseases, primarily hypertension. There was also an active clinical development programme investigating the therapeutic potential of modulating cyclic adenosine monophosphate (cAMP) levels by selective inhibition of phosphodiesterase type 3 (PDE3) for the treatment of heart failure.

At this time, the Pfizer biologists also began to consider the therapeutic possibilities that might arise from modulating intracellular levels of cyclic guanosine monophosphate (cGMP). Nitrates were and still are in widespread clinical use for the treatment of cardiovascular conditions, particularly angina pectoris. Nitrates are an exogenous source of nitric oxide (NO), a labile gas that can diffuse across cell membranes into vascular smooth muscle cells and stimulate the action of soluble guanylate cyclase to convert guanosine triphosphate (GTP) to cGMP. The formation of cGMP then initiates a cascade of reactions that ultimately decreases intracellular calcium levels, thereby promoting relaxation of the smooth muscle. Therefore nitrates, via their relaxant effects on vascular smooth muscle, act as mixed dilators of arteries and veins. The resulting decrease in peripheral vascular resistance and cardiac preload, coupled with improved perfusion of ischaemic areas of the myocardium, leads to a clinically useful anti-anginal effect.

However, the therapeutic potential of nitrates is limited by the rapid induction of tachyphylaxis with prolonged administration. This limitation led some scientists at Pfizer to consider alternative approaches to modulate NO signalling.

PDE5 is selected as a target

Although the precise mechanism of tolerance to nitrates is not clear, any treatment that does not directly increase NO levels might circumvent this problem. The scientific team at Pfizer therefore proposed that a downstream target in the NO/cGMP pathway could be modulated. Cyclic nucleotides (cAMP and cGMP) are degraded by a cascade of reactions that ultimately decreases intracellular levels of cAMP and cGMP. Nitrates were and still are in widespread clinical use for the treatment of cardiovascular diseases, primarily hypertension. There was also an active clinical development programme investigating the therapeutic potential of modulating cyclic adenosine monophosphate (cAMP) levels by selective inhibition of phosphodiesterase type 3 (PDE3) for the treatment of heart failure.

At this time, the Pfizer biologists also began to consider the therapeutic possibilities that might arise from modulating intracellular levels of cyclic guanosine monophosphate (cGMP). Nitrates were and still are in widespread clinical use for the treatment of cardiovascular conditions, particularly angina pectoris. Nitrates are an exogenous source of nitric oxide (NO), a labile gas that can diffuse across cell membranes into vascular smooth muscle cells and stimulate the action of soluble guanylate cyclase to convert guanosine triphosphate (GTP) to cGMP. The formation of cGMP then initiates a cascade of reactions that ultimately decreases intracellular calcium levels, thereby promoting relaxation of the smooth muscle. Therefore nitrates, via their relaxant effects on vascular smooth muscle, act as mixed dilators of arteries and veins. The resulting decrease in peripheral vascular resistance and cardiac preload, coupled with improved perfusion of ischaemic areas of the myocardium, leads to a clinically useful anti-anginal effect.

However, the therapeutic potential of nitrates is limited by the rapid induction of tachyphylaxis with prolonged administration. This limitation led some scientists at Pfizer to consider alternative approaches to modulate NO signalling.

PDE5 is selected as a target

Although the precise mechanism of tolerance to nitrates is not clear, any treatment that does not directly increase NO levels might circumvent this problem. The scientific team at Pfizer therefore proposed that a downstream target in the NO/cGMP pathway could be modulated. Cyclic nucleotides (cAMP and cGMP) are degraded by intracellular PDEs (FIG. 1). In the mid-1980s, five subtypes of PDEs were identified. PDE3 and PDE4 specifically catalyse the breakdown of cAMP, whereas PDE1 and PDE2 catalyse the breakdown of both cAMP and cGMP. The fifth member of this group, PDE5, exclusively catalyses the breakdown of cGMP (TABLE 1). PDE5 is present in the smooth muscle of the systemic vasculature, and in platelets. Studies by Corbin et al. revealed that the regulatory domain in the amino-terminal portion of PDE5 contains a phosphorylation site (serine 92), two allosteric cGMP-binding sites, a and b, and at least a portion of the dimerization domain. The catalytic domain in the carboxy-terminal portion of the protein contains the two Zn2+-binding motifs A and B, and a cGMP substrate-binding site (FIG. 2). In 1986 Pfizer formed a project team of scientists at Sandwich, with the aim of developing a selective inhibitor of PDE5 and evaluating its preclinical pharmacology (TIMELINE). Eventually the team succeeded in synthesizing novel pyrazolopyrimidines that were highly potent inhibitors of PDE5. A compound

Origins of the cGMP/PDE5 project at Pfizer

In the mid-1980s, a very active cardiovascular research programme was based at the Pfizer European research laboratories in Sandwich, UK. Already discovered and under clinical development at Sandwich were various vasodilators, including prazosin (Minipress), doxazosin (Cardura) and amlodipine (Norvasc), which would become well-known products marketed for the treatment of cardiovascular diseases, primarily hypertension. There was also an active clinical development programme investigating the therapeutic potential of modulating cyclic adenosine monophosphate (cAMP) levels by selective inhibition of phosphodiesterase type 3 (PDE3) for the treatment of heart failure.

At this time, the Pfizer biologists also began to consider the therapeutic possibilities that might arise from modulating intracellular levels of cyclic guanosine monophosphate (cGMP). Nitrates were and still are in widespread clinical use for the treatment of cardiovascular conditions, particularly angina pectoris. Nitrates are an exogenous source of nitric oxide (NO), a labile gas that can diffuse across cell membranes into vascular smooth muscle cells and stimulate the action of soluble guanylate cyclase to convert guanosine triphosphate (GTP) to cGMP. The formation of cGMP then initiates a cascade of reactions that ultimately decreases intracellular calcium levels, thereby promoting relaxation of the smooth muscle. Therefore nitrates, via their relaxant effects on vascular smooth muscle, act as mixed dilators of arteries and veins. The resulting decrease in peripheral vascular resistance and cardiac preload, coupled with improved perfusion of ischaemic areas of the myocardium, leads to a clinically useful anti-anginal effect.

However, the therapeutic potential of nitrates is limited by the rapid induction of tachyphylaxis with prolonged administration. This limitation led some scientists at Pfizer to consider alternative approaches to modulate NO signalling.

PDE5 is selected as a target

Although the precise mechanism of tolerance to nitrates is not clear, any treatment that does not directly increase NO levels might circumvent this problem. The scientific team at Pfizer therefore proposed that a downstream target in the NO/cGMP pathway could be modulated. Cyclic nucleotides (cAMP and cGMP) are degraded by intracellular PDEs (FIG. 1). In the mid-1980s, five subtypes of PDEs were identified. PDE3 and PDE4 specifically catalyse the breakdown of cAMP, whereas PDE1 and PDE2 catalyse the breakdown of both cAMP and cGMP. The fifth member of this group, PDE5, exclusively catalyses the breakdown of cGMP (TABLE 1). PDE5 is present in the smooth muscle of the systemic vasculature, and in platelets. Studies by Corbin et al. revealed that the regulatory domain in the amino-terminal portion of PDE5 contains a phosphorylation site (serine 92), two allosteric cGMP-binding sites, a and b, and at least a portion of the dimerization domain. The catalytic domain in the carboxy-terminal portion of the protein contains the two Zn2+-binding motifs A and B, and a cGMP substrate-binding site (FIG. 2). In 1986 Pfizer formed a project team of scientists at Sandwich, with the aim of developing a selective inhibitor of PDE5 and evaluating its preclinical pharmacology (TIMELINE). Eventually the team succeeded in synthesizing novel pyrazolopyrimidines that were highly potent inhibitors of PDE5. A compound

* Medical Clinic II/V, Department of Internal Medicine, University Hospital Gießen and Marburg, GmbH, Klinikstrasse 36, 35392 Gießen, Germany. Pfizer Ltd (ipc 383), Ramsgate Road, Sandwich, Kent CT15 9NJ, UK. Correspondence to H.A.G. e-mail: ardeschir.ghofrani@uglc.de doi:10.1038/nrd2030

** Angina pectoris
Severe chest pains caused by insufficient supply of blood to the heart.

Tachyphylaxis
Reduced responsiveness to a drug that is chronically supplied and requires dose up-titration to maintain the same level of efficacy over time.

© 2006 Nature Publishing Group

© 2006 Nature Publishing Group
designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine, was chosen for further profiling (FIGS 3, 4). It was initially named UK-92,480, but is now better known as sildenafil, of which the citrate salt is marketed under the trade name Viagra. The compound was demonstrated to have very good potency (an IC₅₀ of 3.5 nM against PDE5 derived from human platelets), and excellent selectivity over PDEs 1–4 (REF. 7). Moreover, in preclinical studies, this compound displayed vasodilatory effects, abrogated platelet aggregation, and inhibited thrombus reformation in a damaged carotid artery (modified Folt’s model). Therefore, in 1989 UK-92,480 was selected to undergo further development and eventually entered clinical trials in 1991 (REF. 9).

Clinical development programme for angina

In 1991 studies in healthy volunteers commenced, in which single doses of UK-92,480 up to 200 mg were administered. UK-92,480 had a relatively short plasma half-life (~4 hours)⁹. The doses were generally well tolerated and, at moderate and higher doses, modest reductions in systemic blood pressure and side effects associated with vasodilatation (such as headache and flushing) were observed. At doses of 150 mg and higher, transient disturbances in colour vision perception were reported (later in the development programme, these were demonstrated to be caused by a weak inhibitory effect of UK-92,480 on PDE6 in photoreceptors)¹¹. Subsequently, in a study involving intravenous administration of UK-92,480, a moderate vasodilatory effect was observed in patients with angina. A later study in healthy volunteers that was designed to investigate a potential pharmacodynamic interaction between UK-92,480 and glyceryl trinitrate (GTN) demonstrated that UK-92,480 augmented the vasodilatory and antihypertensive effects of GTN¹². Although this finding was positive in confirming the mode of action of sildenafl in a clinical setting, it was also potentially problematic. UK-92,480 would have to be contraindicated in patients taking nitrates or, alternatively, a safe way of co-administering the two different agents needed to be developed and demonstrated.

In 1992, several multiple-dose, healthy volunteer studies were undertaken to investigate the pharmacokinetics, pharmacodynamics and tolerance of UK-92,480. When administered at doses of up to 75 mg three times per day for 10 consecutive days, some volunteers reported headaches, flushing, indigestion and muscle aches. Some volunteers also reported penile erections as a side effect. Initially this was not considered to be of major significance, because the volunteers were reporting these effects after a mere several days of UK-92,480 administration. Therefore, cardiovascular indications remained the primary focus of ongoing clinical investigations during 1992 and 1993. However, by mid-1993, UK-92,480 was looking less promising as a new treatment for angina pectoris. The relatively short half-life indicated that treatment would have to be administered at least three times per day for the chronic treatment of
During the 1980s, advances were made in the recognition and treatment of erectile dysfunction (ED). Prior to then, many clinicians considered ED to be either a relatively trivial issue and/or a condition that was predominantly attributable to psychological causes. However, urologists interested in ED had started treating their patients with intracavernosal injections of vasodilating drugs (for example, papaverine and prostaglandin E1) that functioned by modulating levels of cAMP. This pharmacological approach worked for many patients, but drawbacks included the invasive nature of the treatment, the induction of an ’artificial’ erection that would often last long after intercourse had finished, with the added risks of local bleeding, bruising and priapism (a prolonged painful erection lasting longer than 6 hours). There was no doubt that an effective oral agent would be a major breakthrough in the treatment of this distressing condition, although at the time few researchers and clinicians in the field thought this was possible.

The decision to undertake pilot studies with sildenafil in ED was supported by the observation that penile erections were a common side effect in the multiple-dose sildenafil Phase I study. Furthermore, emerging data implicated NO as a key mediator of the neural and haemodynamic effects that lead to penile erection in men. In particular, in the early 1990s, Ignarro and others reported that NO is the neurotransmitter that is released from cavernous nerves during sexual stimulation. In order to maximize the chances of detecting a signal, the patients selected for the first two studies were relatively healthy men with ED but no clinically apparent cardiovascular diseases or other underlying risk factors. By mid-1994, after completion of two separate clinical studies, single doses of sildenafil were shown to enhance erectile responses to sexual stimulation and to be well tolerated; moreover, a clear dose–response relationship was observed.

After this initial success, a full development programme was designed. Again, novel clinical trial designs (including the development of a new instrument, the International Index of Erectile Function) were used. Sildenafil was effective in almost all types of patients with ED, including those with diabetes mellitus, cardiovascular disease, multiple sclerosis, spinal cord injury and even in patients who had undergone radical prostatectomy. Efficacy response rates of 70% or higher were consistently observed in clinical trials, although response rates were somewhat lower in post-prostatectomy patients (~40–50%) and those with diabetes mellitus (~60%). Sildenafil was very well tolerated when taken on demand (usually about twice per week) and muscle aches were very rarely reported in the Phase IIb/III programme.

During and after the full development programme, a further six families of PDE (PDEs 6–11) were identified (Table 2). The activity of sildenafil was assessed against representative members of all of these PDE families. Sildenafil exhibited excellent selectivity over PDEs 7–11, but only about tenfold selectivity for PDE5 versus PDE6. Subsequent in vitro and in vivo investigations confirmed that the transient visual side effects observed with sildenafil treatment were almost certainly due to weak inhibition of PDE6, a cGMP-metabolizing enzyme that is present exclusively in photoreceptors. Sildenafil was shown to have similar potency against PDE6 in all species routinely evaluated in toxicological screens, and it was further demonstrated that long-term sustained inhibition of PDE6 by sildenafil (even at doses many times greater than those administered to humans) did not lead to any lasting damage to the structure and function of the eye.

Clinical studies in erectile dysfunction. In late 1993 the first clinical study in patients with ED was undertaken using a very novel trial design. In order to overcome the practical problem of confirming an erectogenic effect while allowing the patients to be sexually stimulated, a Rigiscan device that contains two loops that are placed round the base and tip of the penis was used to monitor and record the girth and hardness of the penis during sexual stimulation. In order to maximize the chances of detecting a signal, the patients selected for the first two studies were relatively healthy men with ED but no clinically apparent cardiovascular diseases or other underlying risk factors. By mid-1994, after completion of two separate clinical studies, single doses of sildenafil were shown to enhance erectile responses to sexual stimulation and to be well tolerated; moreover, a clear dose–response relationship was observed.

After this initial success, a full development programme was designed. Again, novel clinical trial designs (including the development of a new instrument, the International Index of Erectile Function) were used. Sildenafil was effective in almost all types of patients with ED, including those with diabetes mellitus, cardiovascular disease, multiple sclerosis, spinal cord injury and even in patients who had undergone radical prostatectomy. Efficacy response rates of 70% or higher were consistently observed in clinical trials, although response rates were somewhat lower in post-prostatectomy patients (~40–50%) and those with diabetes mellitus (~60%). Sildenafil was very well tolerated when taken on demand (usually about twice per week) and muscle aches were very rarely reported in the Phase IIb/III programme.

During and after the full development programme, a further six families of PDE (PDEs 6–11) were identified (Table 2). The activity of sildenafil was assessed against representative members of all of these PDE families. Sildenafil exhibited excellent selectivity over PDEs 7–11, but only about tenfold selectivity for PDE5 versus PDE6. Subsequent in vitro and in vivo investigations confirmed that the transient visual side effects observed with sildenafil treatment were almost certainly due to weak inhibition of PDE6, a cGMP-metabolizing enzyme that is present exclusively in photoreceptors. Sildenafil was shown to have similar potency against PDE6 in all species routinely evaluated in toxicological screens, and it was further demonstrated that long-term sustained inhibition of PDE6 by sildenafil (even at doses many times greater than those administered to humans) did not lead to any lasting damage to the structure and function of the eye.

| Table 1 | PDE nomenclature and families |
|----------|--------------------------------|
| PDE family | Subfamily (number of splice variants) | Substrate |
| 1 | A (4), B (1), C (5) | cAMP/cGMP |
| 2 | A (3) | cAMP/cGMP |
| 3 | A (1), B (1) | cAMP/cGMP |
| 4 | A (8), B (3), C (4), D (5) | cAMP |
| 5 | A (3) | cGMP |
| 6 | A (1), B (1), C (1) | cGMP |
| 7 | A (3), B (1) | cAMP |
| 8 | A (5), B (1) | cAMP |
| 9 | A (6) | cGMP |
| 10 | A (2) | cAMP/cGMP |
| 11 | A (4) | cAMP/cGMP |

cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; PDE, phosphodiesterase.

© 2006 Nature Publishing Group
Indeed there are now multiple scientific papers suggesting a potential utility of sildenafil in protecting the ischaemic myocardium and in treating stroke.66–69

There have also, since 2000, been occasional case reports66–69 of non-arteritic anterior ischaemic optic neuropathy (NAION) in patients taking sildenafil. Although NAION is the most common acute optic neuropathy in people older than 50 years it is a relatively rare event causing partial visual loss in one eye, and is associated with various risk factors, including cardiovascular disease and a small cup:disk ratio. In a recently published review of clinical trial data,60 Gorkin et al. estimated an incidence of 2.8 cases of NAION per 100,000 patient-years of sildenafil exposure, which is similar to estimates reported in the general US population (2.5–11.8 cases per 100,000 men aged >50 years).31,52 Very recently the original authors of many of these case reports published a further review69 and concluded that most of the case reports of NAION might be an expected coincidence because sildenafil is a top-selling medication and patients who receive the drug are frequently older, vasculopathic and already at risk of NAION. They further conclude that the only patients who need to avoid PDE5 inhibitors for visual reasons are those who have previously suffered NAION in one eye.

At the time of preparing this paper, sildenafil has been on the market as a treatment for ED for more than 7 years. It is now estimated that more than 750,000 physicians have prescribed sildenafil to over 23 million men, and sildenafil remains by far the most widely used treatment for ED.44 Preclinical and clinical investigations continue to add to our knowledge with respect to the mode of action of sildenafil in treating ED, the full scope of ED patients amenable to treatment with sildenafil and the potential for the management of other indications.

Post-marketing studies have revealed that conjunctival injection and epistaxis are relatively rare side effects of sildenafil administration. Contraindications have been extended to include left ventricular outflow obstruction, multiple system atrophy, and additional caution is necessary if patients are receiving alpha-blockers.

Thoughts turn to pulmonary hypertension
After the approval of sildenafil for the treatment of ED, thoughts started to turn to other potential indications for this drug. Sanchez et al.35 observed upregulation of PDE5 gene expression in pulmonary hypertensive lungs. Furthermore, it was observed that zaprinast (M&B 22948), E4021 and dipyridamole (a relatively non-selective PDE inhibitor with PDE5-inhibitory activity) could ameliorate pulmonary pressure in experimental pulmonary hypertension models.56–59 With the availability of the more potent and selective PDE5 inhibitor sildenafil, a series of preclinical and clinical investigations were conducted to examine the therapeutic potential of this approach in pulmonary vascular diseases. The first intravenous placebo control study (Pfizer study 1024) was conducted to evaluate the effect of intravenous administration of sildenafil at various doses. The study was conducted between 1998 and 2000, and showed that sildenafil selectively reduced pulmonary pressure and
pulmonary vascular resistance in more than 80 patients with pulmonary arterial hypertension, pulmonary venous hypertension and pulmonary hypoxic hypertension. It was also observed that the effect reached a plateau at a plasma concentration of 100 ng per ml of sildenafil (G. Butrous, personal communication). During this period, interest in the role of sildenafil in pulmonary hypertension gained significant momentum.

**Pulmonary hypertension: background.** Pulmonary hypertension is a progressive disease of various origins which has a poor prognosis and results in right heart dysfunction. According to the new classification for pulmonary hypertension from the Third World Conference on Pulmonary Hypertension in Venice in 2003 (Ref 62), five subclasses of chronic pulmonary hypertension can be defined. Among these groups, class 1 represents the so-called pulmonary arterial hypertension (PAH) group, which includes a mixture of diseases that have some pathophysiological, histological and prognostic features in common. Idiopathic pulmonary arterial hypertension (iPAH, formerly known as primary pulmonary hypertension (PPH)) is the most prominent, although exceptionally rare, representative of this class, and is a disease for which loss-of-function mutations in the bone morphogenetic protein type 2 receptor (BMPR2) have been identified as one underlying mechanism. Recent randomized controlled trials for drug development in this area have focused on patients suffering from iPAH as well as associated forms including connective tissue disease-associated pulmonary hypertension and pulmonary hypertension secondary to congenital heart disease.

**Previous treatments for pulmonary arterial hypertension.** Continuous infusion of prostacyclin was the first licensed treatment for severe pulmonary arterial hypertension, and this approach has been shown to be life-saving and to improve exercise capacity in controlled clinical trials. However, there are also drawbacks of this therapy inherent both to the nature of the drug, and to the necessity of implanting a continuous central intravenous line. Preserving the advantageous effects of prostacyclin, while avoiding several of its limitations, the concept of aerosolized iloprost (a long-acting prostacyclin analogue) for the treatment of PAH was developed. This therapy is currently approved in the US, Europe and many other countries for the treatment of PAH; however, its use is cumbersome because of the need for frequent inhalation manoeuvres (six to nine times daily) and elaborate nebulization techniques. The first oral drug approved for the treatment of pulmonary arterial hypertension was the non-selective oral endothelin receptor antagonist bosentan. The efficacy of this therapeutic approach has been proven in randomized controlled trials and led to approval in the US and Europe. However, the long-term use of this vasodilator might be limited by liver toxicity, which affects up to 10% of all patients treated. Therefore the search for an ‘ideal’ pulmonary vasodilator that combines high treatment efficacy, pulmonary selectivity, simplicity of administration and reduced side effects continued until the PDE5 inhibitor sildenafil became the focus of investigation.

**Role of PDE5 in the pulmonary vasculature.** Nitric oxide is constitutively produced in the lung by NO synthases (NOS). The main enzymatic source of lung NO production is endothelial (or constitutive) NOS (eNOS), which is located in the vascular endothelium and the airway epithelium. eNOS-derived NO activates soluble guanylate cyclase, which in turn increases intracellular cGMP levels. Adaptation of the perfusion distribution to well-ventilated areas of the lung (ventilation/perfusion (V/Q) matching) is regulated primarily by local NO production, because the most prominent stimulus for...
Alveolar hypoxia

Reduced oxygen levels (<80 mm Hg) in the lung alveoli caused by impaired ventilation (for example, in chronic lung disorders) or reduced oxygen content in the inspired air (for example, at high altitudes).

Hypoxic pulmonary vasoconstriction

Constriction of pulmonary vessels in the presence of alveolar hypoxia, which prevents the perfusion of non-ventilated areas of lung and maintains optimized gas-exchange properties (also known as the von Euler–Liljestrand mechanism).

In 1991, Haynes and colleagues demonstrated that the PDE5 inhibitor zaprinast caused a reduction in the vasoconstrictor response of isolated rat lungs to acute alveolar hypoxia. The same compound was shown to reduce the expression of matrix metalloproteinases (MMP) 2 and 9. Additionally, the degree of fully muscilarized small (<50 µm) pulmonary arteries was decreased.

Clinical experience with sildenafil for the treatment of chronic pulmonary hypertension. The vasodilatory effects of inhaled NO are restricted to the pulmonary vasculature. In addition, NO has a very short half-life, is used as a screening agent for lung vasoreactivity, and is effective in improving gas exchange in selected patients with adult respiratory distress syndrome (ARDS). Weaning from chronic NO treatment in patients with ARDS was facilitated by oral sildenafil. An initial case report of an adult patient suffering from severe pulmonary arterial hypertension and pulmonary hypertension yielded similar results. Sildenafil reduced pulmonary artery pressure and vascular muscularization in lungs from chronically ill rats, and reduced the expression of matrix metalloproteinases (MMP) 2 and 9. Additionally, the degree of fully muscilarized small (<50 µm) pulmonary arteries was decreased.

Investigations with the PDE5 inhibitor sildenafil in isolated perfused rodent lungs demonstrated a marked inhibition of HPV, thereby confirming that PDE5 inhibitors act as potent pulmonary vasodilators. Oral treatment of chronically hypoxic mice with sildenafil prevented the development of pulmonary hypertension. In these studies, Zhao and colleagues also elegantly demonstrated that it was not only eNOS-derived NO that contributed to the effects of the PDE5 inhibitor. The authors suggested the involvement of natriuretic peptides — which increase intracellular cGMP levels via receptor–linkage activation of the particulate guanylate cyclase — by showing that in natriuretic peptide receptor A (NPR-A) knockout mice, the anti-remodelling effects of sildenafil on the pulmonary vasculature and the right ventricle were reduced. Although all of the investigations described above involved initiating the treatment of chronically hypoxic animals at the onset of hypoxia, Sekhri et al. demonstrated that even curative application of sildenafil reduces pulmonary artery pressure and vascular muscularization in the lungs of chronically hypoxic rats.

In essence, these investigations demonstrate that PDE5 inhibition has anti-pulmonary hypertensive effects, with selective effects on the pulmonary vascular resistance. Therefore the selective pulmonary effects of PDE5 inhibitors are most probably attributable to a generally high level of PDE5 in the pulmonary circulation compared with the systemic circulation and the fact that NO production in the lung is high, akin to the situation in the corpus cavernosum. In a recent publication, Itoh et al. investigated the effect of sildenafil alone, or in combination with beraprost, a prostacyclin analogue, on the development of experimental PAH. Long-term administration of sildenafil in a monocrotaline model of pulmonary hypertension resulted in a decrease in right ventricular systolic pressure, right heart hypertrophy and medial wall thickness. The curative properties of sildenafil after the development of pulmonary hypertension yielded similar results. Sildenafil reduced pulmonary artery pressure and vascular muscularization in lungs from chronically ill rats, and reduced the expression of matrix metalloproteinases (MMP) 2 and 9. Additionally, the degree of fully muscilarized small (<50 µm) pulmonary arteries was decreased.

Figure 3 | Comparison of the structures of cGMP, sildenafil and other PDE5 inhibitors. a | The native substrate, cGMP. b | Sildenafil, c | Vardenafil and Tadalafil. cGMP, cyclic guanosine monophosphate; PDE5, phosphodiesterase type 5.
of administration than it is in adult patients. An early study reporting the successful use of oral sildenafil in a child with severe pulmonary hypertension therefore attracted a lot of attention, not only within the medical community but also in the media. Trials addressing the characterization of the acute effects of sildenafil on pulmonary and systemic haemodynamics in a larger number of patients with pulmonary arterial hypertension showed that sildenafil effectively reduced pulmonary vascular resistance in a dose-dependent manner. Notably, the vasodilatory effects were restricted primarily to the pulmonary circulation, and were significantly stronger than the effects seen with inhaled NO. In combination with inhaled iloprost, augmentation of the pulmonary vasodilatory effect of each single agent was observed. Long-term treatment of patients with pulmonary arterial hypertension was investigated in a number of single-centre studies, all confirming the high efficacy and excellent tolerance of chronic oral sildenafil treatment. In patients with deteriorating severe PAH despite ongoing prostanooid treatment, additional long-term administration of oral sildenafil improved exercise capacity and pulmonary haemodynamics. The combination of prostanooids and sildenafil therefore has potential as a possible future treatment for pulmonary hypertension and numerous reports on the clinical use of sildenafil in pulmonary arterial hypertension in uncontrolled trials have been published.

Interestingly, sildenafil seems to also be effective for treating patients with pulmonary hypertension of origins other than primary pulmonary hypertension. In patients suffering from human immunodeficiency virus (HIV)-related pulmonary hypertension, sildenafil was effective in reducing pulmonary vascular resistance, as it was in PPH. Recent data also suggest that long-term oral sildenafil treatment in patients with non-operable chronic thromboembolic pulmonary hypertension is beneficial. The importance of this finding lies in the fact that there is currently little to offer these patients in the way of therapeutic options, with the exception of lung transplantation.

**Pivotal trial and approval of sildenafil for the treatment of PAH (SUPER-1 study).** The growing body of evidence from various studies between 1998–2001, which had already demonstrated the efficacy of sildenafil in the treatment of PAH, led to the design of a large, randomized, controlled, multinational trial to provide final proof of this new treatment concept, and to obtain legal approval for sildenafil as a new treatment for pulmonary arterial hypertension. The SUPER-1 (Sildenafil Use in Pulmonary HyperTension) study started in 2002 and included 278 patients with symptomatic pulmonary arterial hypertension who were treated either with placebo or sildenafil (20, 40 or 80 mg) orally three times daily (TID) for 12 weeks. The primary endpoint in this trial — as in many previous trials with other medications similarly indicated — was the change from baseline to week 12 in the 6-minute walk test. Sildenafil, at all of the applied doses, improved exercise capacity (up to 50 metres placebo-corrected value) in the 80 mg TID group, functional class and haemodynamics, as compared with placebo-treated patients, and was very well tolerated. Additionally, patients completing the double-blind phase were able to enter a long-term extension trial, which was conducted over a 2-year period with 80 mg sildenafil TID. The increase in the 6-minute walk distance achieved after 3 months in the placebo-controlled phase was maintained even after a year of therapy, as were the improvements in functional class, which are both strongly indicative of the maintenance of the effect in spite of the severity of the disease.

Based on the very favourable mid- and long-term effects of this new oral treatment, sildenafil was approved by the FDA and the EMEA in 2005 for the treatment of patients suffering from PAH. Both agencies decided to approve only the 20 mg TID dose, as only a flat (non-significant) dose–effect relationship between 20–80 mg TID was observed regarding the primary endpoint of the study, the change in 6-minute walking distance over 12 weeks of treatment. In addition, analysis of sildenafil plasma levels in the SUPER-1 study showed no dose–effect relationship with the doses studied (Pfizer Chemical Research Group, unpublished data). There is evidence from some clinical and experimental settings that the duration of action of sildenafil might not be accurately reflected by plasma levels and the applied dosage. It has been shown that the affinity of sildenafil for PDE5 is even increased after intracellular phosphorylation of the enzyme. In addition, conformational changes to PDE5 and the slow dissociation rate of sildenafil from the enzyme could contribute to the flat dose–effect relationship. One possible explanation is that sildenafil binding to the catalytic site of PDE5 could occur at higher affinity intracellularly than estimated.
Table 2 | Physiological and/or functional roles of PDEs

| PDE family | Role(s) | Evidence* |
|------------|---------|-----------|
| 1          | Vascular smooth muscle proliferation; Ca^2+ modulation of olfaction | Broad distribution, but highest levels in proliferating vascular smooth muscle cells, testes, heart and neural tissues (for example, olfactory epithelial cells). Binding and inactivation by Ca^2+/calmodulin |
| 2          | Regulation of Ca^2+ channels, olfaction, platelet aggregation and aldosterone secretion | Broad distribution, but highest levels in brain and adrenal cortex |
| 3          | Cardiac contractility, insulin secretion and lipolysis | Broad distribution, but particular abundance in adipose tissue, liver, cardiac muscle, vascular smooth muscle and platelets; inhibited by drugs with cardiotoxic, vasodilatory, thrombolytic, and antiplatelet aggregation properties. Stimulated by insulin, leptin and insulin-like growth factor |
| 4          | Immunological and inflammatory signalling processes; smooth muscle tone; depression | Broad distribution, highest levels in neural and endocrine tissue. Inflammatory cells thought to participate in the pathogenesis of inflammatory diseases (such as asthma and chronic obstructive pulmonary disease) preferentially express PDE4 |
| 5          | Penile erection; smooth muscle tone of vasculature, airways and gastrointestinal tract | Abundant distribution in smooth muscle. The PDE5-specific inhibitor sildenafil has clinical efficacy for the treatment of erectile dysfunction |
| 6          | Vision | Distribution in rod and cone photoreceptor cells. Some visual defects are related to PDE6 mutations |
| 7          | T-lymphocyte activation and proliferation; skeletal muscle metabolism | Distribution is predominantly in T lymphocytes (PDE7A1). PDE7 mRNA is abundant in skeletal muscle tissue, T lymphocytes and B lymphocytes, but protein and activity are readily measurable only in T lymphocytes |
| 8          | T-cell activation | PDE8A mRNA is widely expressed (highest in testis). PDE8B is unique to the thyroid gland |
| 9          | Possibly maintains basal intracellular cGMP levels or natriuresis and vascular tone | mRNA is widely expressed, particularly in spleen, intestine, kidney, heart and brain |
| 10         | Unknown | Human PDE10 is widely distributed |
| 11         | Sperm capacitation; other functions unknown | mRNA occurs at highest levels in skeletal muscle, prostate, kidney, liver, pituitary and salivary glands, and testis. Protein is localized to vascular smooth muscle cells, cardiac myocytes, corpus cavernosum of the penis, prostate and skeletal muscle |

*See REFS 191–196. cGMP, cyclic guanosine monophosphate; PDE, phosphodiesterase.

previously, which might retard clearance of the inhibitor from the cells (G. Butrous, personal communication). On the other hand, however, in the SUPER-1 trial there were clear trends in some secondary endpoints (some showed statistically significant differences between the three applied doses) indicating that, for a subgroup of patients, higher doses might be more efficacious than the approved 20 mg TID dosage. Moreover, in the majority of preceding short- and long-term studies, daily doses of 100–300 mg were investigated and reported to be efficacious and well tolerated147–149,151,158. Future studies are therefore warranted that address the long-term efficacy of 20 mg TID or even lower doses of sildenafil for the treatment of PAH.

**Future indications for PDE5 inhibitors**

Raynaud’s phenomenon and digital ulcers in collagen vascular diseases. Patients with pulmonary arterial hypertension often complain about intermittent, temperature-dependent peripheral vasospasms resulting in perfusion deficiencies in their fingers and toes (so-called Raynaud’s phenomenon) even in the absence of a proven collagen vascular disease129–131. When treated with vasodilators, these symptoms can improve in parallel with, but also independent of, improvements in pulmonary haemodynamics. Raynaud’s phenomenon and digital ulcers are of an even higher prevalence, and are clinically more important, in patients with systemic sclerosis, CREST syndrome (which comprises calcinosis cutis, Raynaud’s phenomenon, oesophageal dysmotility, sclerodactyly and telangiectasia), and systemic lupus erythematosus132. Treatment currently includes the application of calcium-channel blockers, infused prostanoids and alpha-2 blockade133–135. However, the clinical efficacy of these therapies is often modest at best. A growing number of uncontrolled trials indicated that the efficacy of sildenafil for the treatment of digital ulceration and Raynaud’s phenomenon in patients with scleroderma with or without pulmonary hypertension136–138 warranted attention. In an initial randomized controlled trial, Fries et al. investigated the effects of sildenafil (50 mg given twice daily) on the symptoms and capillary perfusion in patients with Raynaud’s phenomenon140. Most notably, only patients previously treated with other vasodilators that showed insufficient improvement were included in this trial. In contrast to the effects of placebo, chronic sildenafil treatment for 4 weeks reduced the mean frequency and duration of Raynaud attacks, and lowered the...
mean Raynaud’s condition score significantly. Moreover, capillary blood flow velocity increased in each individual patient, and the mean capillary flow velocity of all patients more than quadrupled after treatment with sildenafil\(^{140}\). Interestingly, although sildenafil had clear effects in the affected vascular areas, significant reductions of the systemic blood pressure were not reported in any of the aforementioned studies. These findings fit in with the notion of the selectivity of sildenafil for certain vascular beds (such as the pulmonary circulation and corpus cavernosum) and indicates that PDE5 might be differentially expressed in the remodelled vasculature of digital ulcers as opposed to the non-affected regions of the systemic circulation\(^{141}\). Taken together, there is a good rationale to further develop sildenafil as new treatment for Raynaud’s phenomenon and digital ulcerations.

**Pulmonary hypertension associated with ventilatory disorders.** When pulmonary hypertension is associated with interstitial lung disease, systemic administration of vasodilators increases the blood flow to low- or non-ventilated areas of the lung by interfering with the physiological hypoxic vasoconstrictor mechanism. This worsens pre-existent ventilation(V)/perfusion(Q) mismatch and shunt flow\(^{142}\). The decrease in arterial oxygenation and wasting of the small ventilatory reserve of these patients are important negative consequences of this effect. Oral sildenafil, however, caused pulmonary vasodilation in patients with lung fibrosis and pulmonary hypertension, with an overall vasodilatory potency corresponding to that of intravenous prostacyclin. In contrast to the infused prostanoid, selectivity for well-ventilated lung areas was demonstrated for sildenafil, resulting in an improvement, rather than deterioration, of gas exchange\(^{143}\). Pulmonary hypertension impairs right ventricular performance because it increases right-heart afterload. However, it is still unclear to what extent exercise tolerance is limited by this mechanism. In a recent investigation, this issue was addressed under conditions of acute hypoxia at sea level, and prolonged hypoxia at the altitude of Mount Everest Base Camp\(^{144}\). These investigations were performed in healthy volunteers to exclude other confounding factors that might have added to the limitation of exercise tolerance in patients suffering from chronic hypoxia (such as muscle wasting or chronic immobilization). In essence, acute and prolonged hypoxia induced significant pulmonary hypertension in the study subjects. As expected, exercise tolerance was dramatically reduced as a consequence of severe hypoxaemia and significant pulmonary hypertension. Sildenafil significantly reduced pulmonary hypertension under resting conditions, as well as during exercise. The most interesting finding of this study was that the reversal of pulmonary hypertension resulted in an immediate improvement of exercise tolerance, irrespective of improvements in oxygenation. Further studies investigating the effects of acute and chronic sildenafil administration in hypoxic pulmonary hypertension confirmed the anti-pulmonary hypertensive potential, and the beneficial effects of sildenafil on exercise performance, under these conditions\(^{145,146}\). The results of these studies stimulated further investigations that addressed the therapeutic potential of this drug in patients suffering from chronic hypoxic pulmonary hypertension as it occurs in various chronic diseases (such as chronic obstructive pulmonary disease (COPD), interstitial lung disease and obstructive sleep apnoea)\(^{147–150}\). In fact, very recent work supports the possibility of effective treatment of pulmonary hypertension in patients suffering from advanced COPD\(^{151}\). Based on the significant impact of COPD on public health, studies in this field are warranted.

**Heart failure.** Chronic heart load leads to ventricular hypertrophy as an initial process of adaptation and can ultimately result in ventricular dilatation and failure if not treated chronically\(^{152}\). Although cardiac hypertrophy applies both to disorders that lead to left ventricular loading as well as those that lead to right ventricular loading, there are important differences with respect to the reversibility of muscular hypertrophy of both ventricles. Although the right ventricle — even at advanced stages of dilatation and decompensation — can return to almost normal structure and function once the load is effectively reduced, left ventricular hypertrophy is only partly reversible once a certain degree of hypertrophy has been exceeded\(^{153–154}\). In chronic pulmonary hypertension, right ventricular dysfunction is the ultimate cause of death over the course of the disease; however, effective reduction of the pulmonary vascular resistance — after lung transplantation, for example — might reverse right ventricular hypertrophy\(^{155}\). Wilkins et al. have elegantly shown that effective treatment of pulmonary arterial

---

**Exercise tolerance**

Ability to perform physical strain until limited by occurrence of peripheral (muscular) exhaustion, shortness of breath and/or insufficient blood supply to the myocardium (due, for example, to coronary heart disease).
Further insights into the mechanism of action of sildenafil

An interesting further insight into the mode of action of sildenafil comes from several preclinical investigations, including a recent publication by Musicki et al.\textsuperscript{186}, which investigated the effects of long-term treatment of sildenafil in young and aged rats. In aged rats, but not in their young counterparts, sildenafil prolonged erection and increased the protein expression of phosphorylated endothelial nitric oxide synthase (eNOS) and phosphorylated Akt. Therefore the description of the mode of action of sildenafil in erectile dysfunction, and possibly also in pulmonary vascular diseases, can be further elaborated. It can be proposed that the initial increase in NO levels — due to neurogenic stimulation or a result of alveolar distension, for example — is followed by subsequent maintenance of vasodilation by increased endothelial generation of NO via activated eNOS. It can also be speculated that the resulting increase in blood flow, and consequently shear stress, across the vascular endothelial cell surface activates phosphatidylinositol 3-kinase (PI3K)/Akt, which phosphorylate and thereby further activate eNOS. The activated eNOS can then lead to a sustained further release of NO, which acts to maintain the smooth muscle relaxation, vascular engorgement and increased blood flow (see figure). As sildenafil is being explored for other potential indications, and provided there is a dual effect of chronic administration on activation of eNOS and inhibition of the phosphodiesterase type 5 (PDE5), the therapeutic potential for various diseases involving vascular pathology might therefore be greater than originally envisaged.

Cerebral circulation. Various studies have provided compelling evidence for a functional role of the NO-cGMP pathway in the brain.\textsuperscript{173,174} Inhibition of hippocampal NOS resulted in a state-dependent impairment in object recognition\textsuperscript{175}. As no direct influence of PDE5 inhibitors on the overall cerebral blood flow was found\textsuperscript{173,176,177}, the functional changes described in response to these agents were attributed to neuronal alterations\textsuperscript{178}. Static flow-measures might, however, not be the appropriate parameter to characterize changes in microcirculatory adaptation to demand, where this regulation is mediated via neurovascular coupling in a fast and fine-tuned manner\textsuperscript{179–181}. Concerning the cerebral vasculature, numerous studies have addressed the distribution of regional brain perfusion in health and disease states\textsuperscript{176,182–184}. Investigations addressing the cerebral effects of sildenafil showed no changes in overall cerebral blood flow\textsuperscript{173,175,177} after administration of this agent. On the other hand, despite the absence of changes in overall cerebral blood flow, an effect of the PDE5 system on cognitive function\textsuperscript{185}, repair mechanisms after stroke and expression profiles of second messenger levels in distinct brain areas have been proposed\textsuperscript{186,187,188}. This discrepancy might well be reconciled by a recent finding suggesting that sildenafil significantly improves neurovascular coupling while leaving overall cerebral blood flow unchanged\textsuperscript{189}. Furthermore, this finding is in line with previous observations that the initial blood flow response to cortical activity is mainly governed by stimulation of the NO system\textsuperscript{190}. It has also been proposed that there might be therapeutic potential for sildenafil in cerebral ischaemic disorders, because cGMP levels were shown to be inversely correlated with cardiac hypertrophy in an isoproterenol-induced cardiac hypertrophy model in rats\textsuperscript{192}.

However, the potential usefulness of sildenafil in chronic heart failure might result from a variety of actions in addition to an effect on ventricular hypertrophy. A variety of investigations have indicated that sildenafil can be cautiously administered to selected patients with left heart failure\textsuperscript{163–172}. Endothelial function (the capacity of arterioles to enable increases in regional blood flow in response to appropriate stimuli such as ischaemia) is severely limited in chronic congestive heart failure. In an elegant study Katz et al.\textsuperscript{193} showed that sildenafil could improve endothelial function in such patients. Further studies investigating the long-term effects of PDE5 inhibitors in patients with these diseases would therefore be logical. Also, by virtue of its effect on vasodilatation, arterial stiffness and wave reflection, sildenafil has been shown to reduce aortic pressure and the augmentation index, and could therefore have a role in the management of systemic hypertension\textsuperscript{41}.

**Neurovascular coupling**

Mechanism by which local blood flow in the brain is adapted to underlying neuronal activity in a fast and fine-tuned manner.
with an increase in the phosphorylation of glycogen synthase kinase 3 (GSK3), a downstream target of Akt. Co-incubation of neurospheres with sildenafil and LY 294002, a pharmacological inhibitor of phosphatidylinositol 3-kinase (PI3K)/Akt, abolished sildenafil-induced phosphorylation of Akt and GSK3, suggesting that sildenafil enhanced neurogenesis through activation of the PI3K/Akt/GSK3 pathway.

**Conclusion**

Sildenafil started clinical development as an agent for the treatment of hypertension and angina, and subsequently evolved into a revolutionary new oral treatment for erectile dysfunction. Sildenafil was then further developed to become a much-needed new oral treatment for pulmonary arterial hypertension, and has also been shown to be effective in treating severe Raynaud’s phenomenon associated with systemic sclerosis and digital ulceration. Later investigative studies have suggested that sildenafil also has promise in the treatment of respiratory disorders with ventilation/perfusion mismatch, congestive cardiac failure, hypertension and even stroke. Moreover, many years after the original indication was abandoned, single-dose sildenafil was shown to prolong exercise time in men with angina. Although these findings might seem to be quite disparate and unrelated, all of the disorders described above are in fact characterized by regional deficiencies in blood supply. The successful application of a PDE5 inhibitor (as opposed to non-selective vasodilators) to treat these conditions can be understood in terms of the capacity of sildenafil to reverse endothelial dysfunction, and to selectively improve regional blood flow in areas of greatest need. Further applications of PDE5 inhibitors may arise from new insights into the mode of action of chronic sildenafil administration (BOX 1).

Many patients with erectile dysfunction and pulmonary arterial hypertension are now benefiting from advances in our understanding of vascular biology and pathophysiology, and the advent of selective inhibitors of PDE5 (TABLE 3). It is hoped that the clinical potential of this mechanism to treat the other serious medical conditions described above (and others such as pre-eclampsia and certain forms of intrauterine growth retardation) will soon be realized, so that many more patients can benefit from these amazing breakthroughs in science, technology and medicine.

### Table 3 | PDE inhibition and selectivity

| Drug     | PDE1 | PDE2 | PDE3 | PDE4 | PDE5 | PDE6 (rod) | PDE6 (cone) | PDE7A | PDE8A | PDE9A | PDE10A | PDE11A |
|----------|------|------|------|------|------|------------|------------|-------|-------|-------|--------|--------|
| Sildenafil | 0.281 | >30  | >30  | >30  | >30  | 0.0350     | 0.0370     | 0.0340 | 21.3  | 29.8  | 2.61   | 9.80   | 2.73   |
| Tadalafil | >30  | >100 | >100 | >100 | >100 | 0.00674    | 1.260      | 1.30   | >100  | >100  | >100   | >100   | 0.037  |
| Vardenafil| 0.070 | 6.20 | >1.0 | >1.0 | >1.0 | 0.00014    | 0.00350    | 0.0006 | >30   | >30   | 0.581  | 3.0    | 0.162  |

IC₅₀ values were determined using either native enzyme purified from human tissue (PDE1, heart; PDEs 2, 3 and 5, corpus cavernosum; PDE4, skeletal muscle; PDE6, retina) or using recombinant human enzymes expressed in Sf9 cells (PDEs 7–11) and purified by anion-exchange chromatography. Adapted from REF. 29. IC₅₀ drug concentration necessary to inhibit 50% of enzyme activity; PDE, phosphodiesterase.
Laties, A. & Zrenner, E. Viagra (sildenafil citrate) and against all human phosphodiesterase families: Phillips, S. Phosphodiesterase 5 inhibitor profiles Gbekor, E., Bethell, S., Fawcett, L., Mount, N. & tolerability of sildenafil in the treatment of erectile dysfunction in men with cardiovascular disease. Int. J. Clin. Pract. 55, 171–176 (2001).

Fowler, C. J. et al. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 65, 760–705 (2002).

Derry, F. A. et al. Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Neurology 51, 1629–1633 (1995).

Ogura, K. et al. Role of sildenafil citrate in treatment of erectile dysfunction after radical retropubic prostatectomy. Int. J. Urol. 11, 159–165 (2004).

Morales, A., Ginegil, C., Collins, M., Wicker, P. A. & Osterloh, J. H. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int. J. Imp. Res. 10, 195–223 (1998).

Very informative data analysis on safety and tolerability of sildenafil in the treatment of erectile dysfunction from a series of double-blind, placebo-controlled studies and from ten open-label extension studies.

Cheek, E. Bethell, S., Fanetti, L., Mount, N. & Phillips, S. Phosphodiesterase 5 inhibitor profiles against all human phosphodiesterase families: Immediate and long-term pharmacological tools. J. Urol. 76 (Suppl.), S246 (2002).

Lattis, A. & Trenner, E. Viagra (sildenafil citrate) and ophthalmopathy. Prog. Retin. Eye Res. 21, 485–506 (2002).

Marmur, M. F. & Kessler, R. Sildenafil (Viagra) and ophthalmopathy. Surv. Ophthalmol. 44, 153–162 (1999).

Abbott, D. et al. Preclinical safety profile of sildenafil. Int. J. Impot. Res. 16, 498–504 (2004).

Herrmann, H. C., Chang, G., Klugherz, B. D. & Boshier, A., Wilton, L. V. & Shakir, S. A. Evaluation of the safety of sildenafil for male erectile dysfunction: near normalization in men with cardiovascular disease. The Primary Pulmonary Hypertension Study Group. J. Am. Coll. Cardiol. 39, 13–20 (2002).

Hattenhauer, M. G., Leavitt, J. A., Hodge, D. O., Grill, R. & Gray, D. T. Incidence of nonarteritic anterior ischaemic optic neuropathy: Am. J. Ophthalmol. 123, 103–107 (1997).

Johnson, L. N. & Arnold, C. A. Incidence of nonarteritic anterior ischaemic optic neuropathy. J. Neuroophthalmol. 14, 38–44 (1994).

Frauerfelder, F. W., Pomeranz, H. R. & Bhavsar, A. R. Nonarteritic anterior ischaemic optic neuropathy. Int. J. Clin. Pract. 60, 500–505 (2006).

Sildenafil citrate use and the incidence of nonarteritic anterior optic ischaemic neuropathy. Int. J. Clin. Pract. 58, 111–114 (2004).

Folch, J., Lees, M. & Sloane-Stanley, G. A. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226, 497–509 (1957).

Sildenafil affects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 106, 1097–1103 (2002).

Mahmud, A., Hennessy, M. & Feely, J. Effect of sildenafil on exercise performance and arterial inelasticity in surfer. J. Am. Coll. Cardiol. 40, 122–124 (2002).

Halcox, P. J. et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. Circulation 104, 1220–1224 (2001).

Bocchi, E. A. et al. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 106, 1097–1103 (2002).

Michaod, R. D. et al. BMMRP2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am. J. Hum. Genet. 68, 92–102 (2001).

Gale, N., Mares, A. & Brau, A. Emerging medical therapies for pulmonary arterial hypertension. Prog. Cardiovasc. Dis. 45, 215–224 (2002).

Barst, R. J. et al. Comparative efficacy of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. Am. J. Respir. Crit. Care Med. 156, 1159–1165 (1997).

Badesch, D. B. et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the spectrum of idiopathic or IPH. Circulation 124, 28–35 (2006).

Olschewski, H. et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 164, 820–824 (1996).

Olschewski, H. et al. Inhaled iloprost to treat severe pulmonary hypertension: German PPH Study Group. Am. J. Respir. Crit. Care Med. 162, 435–443 (2000).

Olschewski, H. et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347, 522–529 (2002).

Olschewski, H. et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 128, 1902–1909 (2005).

Channick, R. et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J. Heart Lung Transplant. 22, 624–626 (2003).

Rubin, L. J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896–903 (2002).

Bohle, R. M. et al. Cell-type specific mRNA quantitation in non-neoplastic tissues after laser-assisted cell picking. Pathobiology 60, 191–195 (1995).
Experimental study providing evidence for the anti-thrombotic effect of sildenafil in human pulmonary artery cells.

88 Corbin, J. D., Beasley, A., Blount, M. A. & Francis, S. H. High lung blood flow for treating pulmonary hypertension with PDE5 inhibitors. Biochem. Biophys. Res. Commun. 334, 950–958 (2005).

90 Notable work that explains on a cellular and molecular level the selectivity of PDE5 inhibitors for the pulmonary circulation.

93 Haynes, J., Jr., Kithas, P. A., Taylor, A. E. & Strada, S. Selective inhibition of cGMP-inhibitable cAMP phosphodiesterase decreases pulmonary vasoreactivity. Am. J. Physiol. 261, H467–H492 (1991).

96 Branner, D. A., Fineman, J. R., Chang, R. & Soifer, S. J. Modulation of PDE5 phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am. J. Physiol. 265, H252-H258 (1993).

99 Cohen, A. H. et al. Inhibition of cyclic 3′5′ guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J. Clin. Invest. 97, 172–179 (1996).

102 Zhao, L. et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104, 426–428 (2001).

105 Zhao, L., Mason, N. A., Strange, J. W., Walker, H. & Wilkins, M. R. Beneficial effects of phosphodiesterase 5 inhibitor sildenafil in pulmonary hypertension and lung endothelial nitric oxide synthase from smooth muscle increases fetal lung cGMP phosphodiesterase as a selective pulmonary vasodilator in childhood pulmonary arterial hypertension with oral sildenafil citrate. Am. J. Respir. Crit. Care Med. 169, 536–546 (2004).

108 Itoh, T. Sildenafil for chronic pulmonary hypertension. J. Am. Coll. Cardiol. 43, 1149–1153 (2004).

111 Notable work that explains on a cellular and molecular level the selectivity of PDE5 inhibitors for the pulmonary circulation.

114 Abrams, D., Schulze-Neick, I. & Magee, A. G. Sildenafil as a selective pulmonary vasodilator in children primary pulmonary hypertension. Heart 84, E4 (2004).

117 First case report on the successful long-term therapy of one adult patient with severe idiopathic pulmonary arterial hypertension with oral sildenafil.

120 Abram, D., Schulze-Neick, I. & Magee, A. G. Sildenafil as a selective pulmonary vasodilator in children primary pulmonary hypertension. Heart 84, E4 (2004).

123 First case report on the successful long-term therapy of one adult patient with severe idiopathic pulmonary arterial hypertension with oral sildenafil.

126 Michelakis, E. D. et al. Long-term treatment with oral sildenafil is safe and improves exercise capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108, 2066–2069 (2003).

129 CELORIA, G. C., FRIEDEL, G. H. & SOMMERS, S. C. Raynaud’s disease and primary pulmonary hypertension. Clin. Chest Med. 18, 495–505 (1997).

132 Smith, W. M. & KROOP, I. G. Raynaud’s disease in primary pulmonary hypertension. JAMA 165, 1245–1248 (1957).

135 DATE, G. E. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Am. J. Med. 115, 343–349 (2003).

138 Milestone report on the natural course of primary pulmonary hypertension based on data from the National Institutes of Health. A report from the currently published studies refer to this report if comparisons to a historic control are required.

141 Kallenberg, C. G. Overlapping syndromes, undifferentiated connective tissue diseases, and other fibrosing conditions. Curr. Opin. Pulm. Med. 7, 568–573 (1995).

144 Pope, J. et al. Ioprost and citoplast for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst. Rev. CD000953 (2000).

147 Belch, J. J. & Ho, M. Pharmacotherapy of Raynaud’s phenomenon. Drugs 52, 682–695 (1996).

150 Boin, F. & Wigley, F. M. Understanding, assessing and treating Raynaud’s phenomenon. Drugs. Eur. Respir. 17, 752–760 (2005).

153 Kamata, Y., Kamimura, T., Iwamoto, M. & Minota, S. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud’s phenomenon in a patient with systemic sclerosis. Clin. Exp. Dermatol. 30, 451 (2005).

156 Gore, J. & Silver, R. Oral sildenafil for the treatment of Raynaud’s phenomenon and digital ulcers secondary to systemic sclerosis. Ann. Rheum. Dis. 64, 1387 (2005).

159 Rosenkranz, S. et al. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon. Am. J. Res. 139, 871–877 (2004).

162 Lichtenstein, J. R. Use of sildenafil citrate in Raynaud’s phenomenon: comment on the article by Thompson et al. Arthritis Rheum. 48, 282–283 (2005).

165 Fries, R., Shariat, K. von, W.H. & Böhm, M. Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112, 2980–2985 (2005).

168 Original report of the first randomized controlled trial proving the efficacy of sildenafil to treat Raynaud’s phenomenon.

171 Maurice, D. H. et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol. Pharmacol. 64, 553–560 (2003).

174 Agusti, A. G. & Rodriguez-Rosin, R. Effect of pulmonary hypertension on gas exchange. Eur. Respir. J. 21, 1671–1707 (2003).

177 Charnel, H. A. et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360, 895–900 (2002). The first clinical study to show that an oral vasodilator (sildenafil) can improve gas exchange, with comparable effects to those achievable with inhaled nitric oxide.

180 Charnel, H. A. et al. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann. Intern. Med. 141, 169–177 (2004).

183 This randomized controlled trial proved for the first time that effective treatment of hypoxic pulmonary hypertension with sildenafil results in improvements of exercise capacity and right heart function under such conditions.

186 Richalet, J. P. et al. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am. J. Respir. Crit. Care Med. 171, 275–281 (2005).

189 Hsu, A. R. et al. Sildenafil improves cardiac output and exercise performance during high altitude hypoxia, but not normoxia. J. Appl. Physiol. (2006).

192 Naeije, R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2, 20–22 (2005).

195 Higenbottam, T. Pulmonary hypertension and chronic obstructive pulmonary disease: a case for treatment. Proc. Am. Thorac. Soc. 2, 12–19 (2005).
168. Lepore, S. & Skrygan, M., Schmidt, W. E. & Bastian, A. Sildenafil improves hemodynamic parameters in COPD-an investigation of six patients. Pulm. Pharmacol. Ther. (2005).

169. Angerer, P. et al. Ischemic cardiomyopathy: myocyte cell loss, myocyte cellular hypertrophy, and myocyte cellular hyperplasia. Am. J Pathol. 152, 47–64 (1995).

170. Hassan, M. A. & Ketat, A. F. Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. Hypertens. (1995).

171. Nakano, K. & Inohara, S. Regional distribution of human cerebral vascular smooth muscle cells and response to neurotrophic factors. Brain 126, 241–247 (2003).

172. Polack, F. V. et al. Regression of chronic hypoxia-induced pulmonary hypertension, right ventricular hypertrophy, and fibrosis: effect of enalapril. Cardiovasc. Drugs Ther. 11, 177–185 (1997).

173. Seland, H. & O’Brien, S. F. Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. Pulm. Pharmacol. Ther. (2005).

174. Blockland, A., Prickaerts, J., Honig, W. & de Vente, J. Reverse cardiac remodelling in patients with primary pulmonary hypertension after sildenafil treatment. Eur. Respir. J. Suppl. 22, 1142–1143 (2001).

175. Groth, P. et al. Cyclic GMP phosphodiesterase 5A prevents and reverses pulmonary hypertension. Eur. Respir. J. Suppl. 26, 351–361 (2005).

176. Wang, L., Cang, Z. Z., Lan, Z. R. & Chopp, M. Activation of the PI3-K/Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. J. Cereb. Blood Flow Metab. 25, 1150–1158 (2005).

177. Hayashi, M. et al. Molecular cloning and characterization of human PDE5, a novel thyroid-specific isozyme of 5’-cyclic nucleotide phosphodiesterase. Biochem. Biophys. Res. Commun. 250, 761–766 (1999).

178. Beavo, J. A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75, 725–748 (1995).

179. Pyne, N. J. & Furman, B. L. Cyclic nucleotide phosphodiesterases in pancreatic islets. Diabetologia 46, 1179–1189 (2003).

180. Gavras, H., Valsasina, S., Schaefer, J. A., J. V. & Beavo, J. A. Cyclic nucleotide phosphodiesterases in microvascular and endothelial cells. Curr. Atheroscler. Rep. 2, 126–140 (2000).

181. Seland, H. & O’Brien, S. F. Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. Pulm. Pharmacol. Ther. (2005).

182. Aladini, A. et al. Efficacy and safety of sildenafil in the evaluation of intracoronary stenting in severely stenosed coronary artery. Am. J. Cardiol. 94, 1475–1477 (2004).

183. Yuan, J. G., Gao, J. Y., Li, H. Y., Zhang, W. & Li, S. Intravenous administration of human PDE5A2: cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. J. Cereb. Blood Flow Metab. 25, 1150–1158 (2005).

184. Wang, L., Cang, Z. Z., Lan, Z. R. & Chopp, M. Activation of the PI3-K/Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. J. Cereb. Blood Flow Metab. 25, 1150–1158 (2005).

185. Musci, B. et al. Erection capability is potentiated by long-term sildenafil treatment: role of blood flow-induced endotelial nitric oxide synthase phosphorylation. Mol. Pharmacol. 68, 226–232 (2005).

186. Inaba, S., Watanabe, K., Kikumura, K., Takemoto, Y. & Saito, C. Intriguing investigation suggesting a new mechanistic explanation for the long-term effects induced by sildenafil treatment, which differ from short-term vasodilatory effects of the same drug. Am. J. Physiol. 290, 214–222 (2006).

187. Francis, S. H., Turko, I. V. & Corbin, J. D. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65, 1–52 (2001).

188. Kawate, T. P. Cyclic S5’-nucleotide phosphodiesterase isoforms in cell biology and pathophysiology of the kidney. Kidney Int. 55, 29–62 (1999).

189. Hayashi, M. et al. Molecular cloning and characterization of human PDE5B, a novel thyroid-specific isozyme of 5’-cyclic nucleotide phosphodiesterase. Biochem. Biophys. Res. Commun. 250, 761–766 (1999).

190. Seland, H. & O’Brien, S. F. Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. Pulm. Pharmacol. Ther. (2005).

191. Wang, L., Cang, Z. Z., Lan, Z. R. & Chopp, M. Activation of the PI3-K/Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. J. Cereb. Blood Flow Metab. 25, 1150–1158 (2005).

192. Musci, B. et al. Erection capability is potentiated by long-term sildenafil treatment: role of blood flow-induced endotelial nitric oxide synthase phosphorylation. Mol. Pharmacol. 68, 226–232 (2005).

193. Inaba, S., Watanabe, K., Kikumura, K., Takemoto, Y. & Saito, C. Intriguing investigation suggesting a new mechanistic explanation for the long-term effects induced by sildenafil treatment, which differ from short-term vasodilatory effects of the same drug. Am. J. Physiol. 290, 214–222 (2006).

194. Francis, S. H., Turko, I. V. & Corbin, J. D. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65, 1–52 (2001).

195. Kawate, T. P. Cyclic S5’-nucleotide phosphodiesterase isoforms in cell biology and pathophysiology of the kidney. Kidney Int. 55, 29–62 (1999).

196. Hayashi, M. et al. Molecular cloning and characterization of human PDE5B, a novel thyroid-specific isozyme of 5’-cyclic nucleotide phosphodiesterase. Biochem. Biophys. Res. Commun. 250, 761–766 (1999).

197. Seland, H. & O’Brien, S. F. Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. Pulm. Pharmacol. Ther. (2005).

198. Wang, L., Cang, Z. Z., Lan, Z. R. & Chopp, M. Activation of the PI3-K/Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. J. Cereb. Blood Flow Metab. 25, 1150–1158 (2005).

199. Musci, B. et al. Erection capability is potentiated by long-term sildenafil treatment: role of blood flow-induced endotelial nitric oxide synthase phosphorylation. Mol. Pharmacol. 68, 226–232 (2005).

200. Inaba, S., Watanabe, K., Kikumura, K., Takemoto, Y. & Saito, C. Intriguing investigation suggesting a new mechanistic explanation for the long-term effects induced by sildenafil treatment, which differ from short-term vasodilatory effects of the same drug. Am. J. Physiol. 290, 214–222 (2006).